Phase 1: DLT for each cohort of enrolled patients
| Cohort . | Dose (mg/day) . | DLTs, n . | Type of DLTs . | Updated estimated probability of DLT per dose level . | |||
|---|---|---|---|---|---|---|---|
| 1 mg . | 1.5 mg . | 2 mg . | 2.5 mg . | ||||
| 1 | 1.5 | 1 | Grade 4 thrombocytopenia | 0.237 | 0.298 | 0.409 | 0.553 |
| 2 | 1.0 | 0 | — | 0.104 | 0.145 | 0.232 | 0.376 |
| 3 | 2.0 | 0 | — | 0.051 | 0.076 | 0.136 | 0.255 |
| 4 | 2.5 | 1 | Grade 3 neuropathy | 0.052 | 0.078 | 0.139 | 0.259 |
| 5 | 2.5 | 1 | Grade 3 hepatic | 0.052 | 0.078 | 0.139 | 0.259 |
| 6 | 2.5 | 1 | Grade 4 thrombocytopenia | 0.052 | 0.077 | 0.138 | 0.258 |
| Cohort . | Dose (mg/day) . | DLTs, n . | Type of DLTs . | Updated estimated probability of DLT per dose level . | |||
|---|---|---|---|---|---|---|---|
| 1 mg . | 1.5 mg . | 2 mg . | 2.5 mg . | ||||
| 1 | 1.5 | 1 | Grade 4 thrombocytopenia | 0.237 | 0.298 | 0.409 | 0.553 |
| 2 | 1.0 | 0 | — | 0.104 | 0.145 | 0.232 | 0.376 |
| 3 | 2.0 | 0 | — | 0.051 | 0.076 | 0.136 | 0.255 |
| 4 | 2.5 | 1 | Grade 3 neuropathy | 0.052 | 0.078 | 0.139 | 0.259 |
| 5 | 2.5 | 1 | Grade 3 hepatic | 0.052 | 0.078 | 0.139 | 0.259 |
| 6 | 2.5 | 1 | Grade 4 thrombocytopenia | 0.052 | 0.077 | 0.138 | 0.258 |
The dose level closest to the toxicity target (0.25) is in bold.